user

Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma

被引：0
|
作者：
Mollica, Veronica [1 ]
Rizzo, Alessandro [1 ]
Massari, Francesco [1 ]
机构：
[1] Univ Bologna, IRCCS Azienda Osped, Bologna, Italy
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2021年 / 385卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：956 / 957
页数：2
相关论文
共 50 条
  • [41] Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary
    Bajorin, Dean F.
    Witjes, J. Alfred
    Gschwend, Juergen E.
    Schenker, Michael
    Valderrama, Begona P.
    Tomita, Yoshihiko
    Bamias, Aristotelis
    Lebret, Thierry
    Shariat, Shahrokh F.
    Park, Se Hoon
    Ye, Dingwei
    Agerbaek, Mads
    Enting, Deborah
    McDermott, Ray
    Gajate, Pablo
    Peer, Avivit
    Milowsky, Matthew, I
    Nosov, Alexander
    Antonio Jr, Joao Neif
    Tupikowski, Krzysztof
    Toms, Laurence
    Fischer, Bruce S.
    Qureshi, Anila
    Collette, Sandra
    Unsal-Kacmaz, Keziban
    Broughton, Edward
    Zardavas, Dimitrios
    Koon, Henry B.
    Galsky, Matthew D.
    [J]. FUTURE ONCOLOGY, 2023, 19 (06) : 413 - 426
  • [42] Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma?
    Kumar, Naveen
    [J]. INDIAN JOURNAL OF UROLOGY, 2021, 37 (04) : 369 - 371
  • [43] ATTRIBUTES INFLUENCING CHOICE OF ADJUVANT TREATMENT FOR MUSCLE-INVASIVE UROTHELIAL CANCER: QUALITATIVE RESEARCH
    Broughton, E.
    Steinberg, G.
    Harrison, M.
    Braverman, J.
    Alhasani, H.
    Beusterien, K.
    King-Concialdi, K.
    Wayser, G.
    [J]. VALUE IN HEALTH, 2021, 24 : S60 - S60
  • [44] Activation of the mTOR pathway as a potential therapeutic target in muscle-invasive urothelial carcinoma
    Hansel, Donna
    Orloff, Mohammed
    Harwalker, Jyoti
    Platt, Eric
    Sethu, Swathi
    Hicks, Jessica
    De Marzo, Angelo
    Steinle, Roxanne
    Hsi, Eric
    Eng, Charis
    [J]. CANCER RESEARCH, 2009, 69
  • [45] Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder
    Softness, Kenneth
    Kaul, Sumedh
    Fleishman, Aaron
    Efstathiou, Jason
    Bellmunt, Joaquim
    Kim, Simon P.
    Korets, Ruslan
    Chang, Peter
    Wagner, Andrew
    Olumi, Aria F.
    Gershman, Boris
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (06) : 272.e1 - 272.e9
  • [46] Avelumab as neoadjuvant therapy in subjects with muscle-invasive urothelial carcinoma (AURA trial).
    Chanza, Nieves Martinez
    Roumeguere, Thierry Andre
    Sideris, Spyridon
    Gil, Thierry
    Peltier, Alexandre
    Awada, Ahmad
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [47] Cancer Stem Cell Marker Expression in Muscle-Invasive Urothelial Carcinoma.
    Diaz, E.
    Ching, C. B.
    Elson, P.
    Hansel, D. E.
    [J]. MODERN PATHOLOGY, 2011, 24 : 188A - 188A
  • [48] Bioinformatic Identification of Potential Hub Genes in Muscle-Invasive Bladder Urothelial Carcinoma
    Guo, Changgang
    Shao, Ting
    Wei, Dadong
    Li, Chunsheng
    Liu, Fengjun
    Li, Minghui
    Gao, Zhiming
    Bao, Guochang
    [J]. CELL TRANSPLANTATION, 2020, 29
  • [49] Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs
    Shingo Maeda
    Kosei Sakai
    Kenjiro Kaji
    Aki Iio
    Maho Nakazawa
    Tomoki Motegi
    Tomohiro Yonezawa
    Yasuyuki Momoi
    [J]. Scientific Reports, 12
  • [50] Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder
    Hensley, Patrick J.
    Goodwin, Jeffrey
    Davenport, Daniel L.
    Strup, Stephen E.
    James, Andrew
    [J]. CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : E851 - E858
12345